The use of glycoprotein IIb/IIIa inhibitors in elective PCI – A systematic review and meta-analysis of randomised trials
Vascular Pharmacology · 2025
DOI: 10.1016/j.vph.2025.107500 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Vascular Pharmacology, 2025. Verfasst von Daniel G Brieger und 4 weiteren Autor:innen. Beteiligte Einrichtung: Royal North Shore Hospital, St Leonards, Sydney, NSW, Australia; University of Sydney, Camperdown, Sydney, NSW, Australia. Electronic address: daniel…. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Platelet Glycoprotein GPIIb-IIIa Complex, Platelet Aggregation Inhibitors, Coronary Artery Disease. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Glycoprotein IIb/IIIa inhibitors (GPIs) improve 30-day outcomes when used as an adjunct to percutaneous coronary intervention (PCI) in acute coronary syndromes, but their role in stable coronary artery disease (CAD) remains uncertain in the context of modern stents and oral antiplatelet therapy. METHODOLOGY: A systematic search of PubMed, EMBASE, Central and clinicaltrials.gov databases was conducted from inception to October 2022. Randomised trials comparing GPI to placebo in elective PCI were included. Outcomes included target vessel revascularisation (TVR), stent thrombosis (ST) and a composite of TVR, myocardial infarction and death (MACE) at 30-days and 6-12 months. Bleeding was assessed using Thrombolysis In Myocardial Infarction bleeding score or equivalent. A random-effects model was used for all analyses. RESULTS: Of 2375 abstracts screened, 16 studies (6428 patients) were included. GPIs significantly reduced 30-day MACE (risk ratio [RR] 0.58, 95 % CI, 0.39-0.86, p < 0.01; number needed to treat = 33), intermediate-term MACE at 6-12 months (RR 0.67; 95 % CI, 0.49-0.92; p = 0.01) and ST (RR 0.29, 95 % CI, 0.10-0.83, p = 0.02). There was no significant difference in TVR or major bleeding, although minor bleeding was increased (RR 1.72, 95 % CI, 1.14-2.61, p = 0.01, number needed to harm = 77). Meta-regression suggested that the benefit of GPIs has diminished over time. CONCLUSION: GPI use during elective PCI reduces MACE and ST whilst increasing minor bleeding. The observed benefit appears to have waned over time, highlighting the importance of selective use in patients at low bleeding risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Royal North Shore Hospital, St Leonards, Sydney, NSW, Australia; University of Sydney, Camperdown, Sydney, NSW, Australia. Electronic address: daniel.brieger@sydney.edu.au.
- Royal North Shore Hospital, St Leonards, Sydney, NSW, Australia; University of Sydney, Camperdown, Sydney, NSW, Australia.
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Zitieren
APA
Brieger, D. G., Rao, K., Nagaraja, V., Bhindi, R., & Allahwala, U. K. (2025). The use of glycoprotein IIb/IIIa inhibitors in elective PCI – A systematic review and meta-analysis of randomised trials. Vascular Pharmacology. https://doi.org/10.1016/j.vph.2025.107500
Vancouver
Brieger DG, Rao K, Nagaraja V, Bhindi R, Allahwala UK. The use of glycoprotein IIb/IIIa inhibitors in elective PCI – A systematic review and meta-analysis of randomised trials. Vascular Pharmacology. 2025. doi:10.1016/j.vph.2025.107500
BibTeX
@article{Brieger2025,
author = {Brieger, Daniel G and Rao, Karan and Nagaraja, Vinayak and Bhindi, Ravinay and Allahwala, Usaid K},
title = {The use of glycoprotein IIb/IIIa inhibitors in elective PCI – A systematic review and meta-analysis of randomised trials},
journal = {Vascular Pharmacology},
year = {2025},
doi = {10.1016/j.vph.2025.107500}
}
EUVIMED